What did Cowen & Co. change about the NBTX analyst rating on March 12, 2026?

Cowen & Co. maintained a **Buy** rating on March 12, 2026, keeping Nanobiotix S.A. (NBTX) on its Europe Best Ideas list. The note did not include a fresh price target and is a reaffirmation, not an upgrade.

Does the Cowen note include an NBTX price target?

No. Cowen’s March 12, 2026 note maintained a **Buy** but did not publish a new NBTX price target. The absence suggests stable conviction rather than a valuation update.

How should investors treat this NBTX analyst rating?

Treat the maintained Buy as one input. Combine the NBTX analyst rating with clinical news, financials, and price action before changing allocations. Use risk controls given biotech volatility.

What is Meyka AI’s view on NBTX after the Cowen note?

Meyka AI rates NBTX **B+**, reflecting benchmark, sector, growth, metrics, and analyst consensus. This grade supports Cowen’s maintained Buy as consistent with a positive, but not definitive, outlook.

Analyst Ratings

Cowen & Co. Maintains Buy on NBTX Nanobiotix S.A. March 12, 2026

ByHuzaifa Zahoor March 13, 2026March 13, 2026

Cowen & Co. maintained a Buy rating on Nanobiotix S.A. (NBTX) on March 12, 2026. This NBTX analyst rating kept the stock on Cowen’s Europe Best Ideas list, according to StreetInsider. The note did not add a fresh price target, and trading moved -1.31% (-$0.42) after the bulletin. Investors should read this as continued analyst conviction rather than a new directional call, and weigh the update with company fundamentals and sector momentum.